Novel Approaches with HIF-2α Targeted Therapies in Metastatic Renal Cell Carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Germline and somatic Von Hippel-Lindau (VHL) gene mutations are key drivers in hereditary and sporadic renal cell carcinoma (RCC).
• VHL inactivation leads to constitutive activation of hypoxia-inducible factor-2 alpha (HIF-2α), promoting tumor angiogenesis and growth.
• Belzutifan, an HIF-2α inhibitor, is approved for VHL-associated and metastatic RCC (mRCC), but resistance is a concern.

Purpose of the Study:

• To review potential resistance mechanisms to belzutifan, the sole approved HIF-2α inhibitor.
• To discuss ongoing clinical trials combining belzutifan with other therapies to overcome resistance.
• To explore emerging HIF-2α inhibitors and future directions for mRCC treatment.

Main Methods:

• Literature review of VHL disease, RCC pathogenesis, and HIF-2α inhibitor mechanisms.
• Analysis of current clinical trial data for belzutifan combinations.
• Discussion of preclinical and early clinical investigations of next-generation HIF-2α inhibitors.

Main Results:

• Resistance to HIF-2α inhibitors like belzutifan can emerge through various mechanisms.
• Combination therapies involving belzutifan with targeted agents or immune checkpoint inhibitors show promise in early trials.
• Newer HIF-2α inhibitors are under development, potentially offering improved efficacy and overcoming resistance.

Conclusions:

• Novel strategies are needed to address belzutifan resistance in mRCC.
• Combination therapies and next-generation inhibitors represent promising avenues for improving HIF-2α targeting.
• Further research is crucial to overcome challenges and optimize HIF-2α inhibitor use in mRCC treatment.